Pathway Targeted Immunotherapy: Rationale and evidence of durable clinical responses with a novel, EGF-directed agent for advanced NSCLC

Around 85% of lung malignancies are NSCLCs.1 The most frequently encountered mutations are in EGFR and KRAS, and these mutations are mutually exclusive. In NSCLC, overexpression of EGFR has been associated with poor prognosis.